Abstract: Double-protected needle assembly comprising a needle-handle portion and a needle-protecting portion. The needle-handle portion includes a bevel-tipped needle attached to and extending from it into the needle-protector portion. The needle protecting portion comprises a rigid, tamper proof member completely enclosing the needle and attached to the needle-handle portion at a resilient tear seal member adapted to break when a twisting force is applied to either the handle portion or the protecting member. The tear seal is adapted to remove liquid from the surface of the needle when the protector is withdrawn to expose the needle. Within the protector, but not attached thereto, is a relatively soft inner tubular enclosure completely enclosing the needle extending beyond its bevel tip and adapted to prevent contact of the bevel tip with any portion of the rigid protector during assembly or when the protector is removed.

Abstract: A method and system is disclosed for introducing anti-bacterial agents, for example, quinolone carboxylic acid derivatives into blood bag systems for preventing massive bacteria growth in stored blood and blood components. The quinolone carboxylic acid derivative can be added to a collection container before, during or after the collection of blood and blood components. The addition of a quinolone carboxylic acid derivative to blood bag systems allows for increase in storage time for blood and blood components without the threat of massive bacterial contamination.

Abstract: Method and composition for providing a non-toxic, sterile, virally inactivated human transferrin preparation for use in cell culture systems. The method comprises saturation of the transferrin with an excess of iron, removal of free iron radicals and unwanted proteins, and pasteurization of the iron-bound transferrin substantially free of iron radicals.

Abstract: There is disclosed a process for treating gram negative septicemia/endotoxemia to decrease lung damage in a host by parenterally administering a therapeutically effective amount of antithrombin III and alpha-1-proteinase inhibitor.

Abstract: Affinity purification of Factor VIII:C, both plasma derived and genetically engineered, using coupled phosphatidylserine (PS) as the predominant phospholipid (PH) results in a high degree of purity of Factor VIII:C, similar to that previously demonstrated with monoclonal antibodies specific to either Factor VIII:C or von Willebrand factor. Phospholipids that can be used in combination with PS are phosphatidycholine (PC) and phosphatidylethanolamine (PE).

Abstract: A method for increasing the survival rate in hypercatabolic mammals following the onset of burn wound sepsis. The method comprises orally administering to the mammal, sufficient doses of ciprofloxacin to attain high concentrations in extra vascular fluid, and parenterally administering to the mammal, Pseudomonas immune globulin. The combination therapy of treating Pseudomonas burn wound sepsis with ciprofloxacin and Pseudomonas immune globulin results in a higher rate of survival than the treatment utilizing a single agent. This suggests a synergistic interaction between the two agents in the therapy of polymicrobial burn wound sepsis.

Abstract: There is disclosed a non-carbohydrate sulfated matrix and the use thereof to isolate and purify blood clotting factors and other blood proteins by a procedure involving the adsorption of at least one of such factors and proteins onto the non-carbohydrate sulfated matrix followed by elution of such factors and proteins onto the non-carbohydrate sulfated matrix followed by elution of such factors and proteins from the matrix.

Abstract: There is disclosed a method for separating alpha-1-proteinase inhibitor (also known as alpha-1 antitrypsin) from an aqueous solution of plasma proteins, especially from Cohn Effluent II & III and Cohn Effluent I. The method includes the steps of first treating the aqueous solution to lower the concentration of salts therein and, optionally, its alcohol content, contacting the resulting solution with an anion exchange resin having selective affinity for alpha-1-proteinase inhibitor to selectively bind the alpha-1-proteinase inhibitor and allow unwanted plasma proteins to elute through the resin, displacing the alpha-1-proteinase inhibitor from the resin and recovering the same.

Abstract: There is disclosed an immunizing composition comprising a non-toxic polysaccharide isolated from gram-negative bacteria, especially from Pseudomonas aeruginosa, covalently coupled to a non-toxic protein from the gram-positive bacterium Micrococcus luteus by means of a 4-12 carbon moiety. To prepare the above immunizing agent, the lipid A portion of lipopolysaccharide from a gram-negative bacterium is separated to give a non-toxic polysaccharide. Reactive aldehyde groups are generated on the non-toxic polysaccharide by selective oxidation. The non-toxic polysaccharide is then covalently coupled to a non-toxic protein isolated from said gram-positive bacterium, Micrococcus luteus, by means of a polyfunctional compound having 4-12 carbon atoms and having at least two functional groups which are reactive to the aldehyde groups on the non-toxic polysaccharide and to the carboxylic groups on the non-toxic protein.

Abstract: There is disclosed a process for producing a convalently bound heparin--antithrombin-III complex useful for anticoagulant therapy, a covalently bound heparin--antithrombin-III complex produced by the process, a composition thereof in a pharmaceutically acceptable carrier, and a method for preventing and treating thromboembolisms by administering to a human patient a therapeutically effective amount of the complex or preparation.

Abstract: There is disclosed an improved method for separating and recovering proteins, particularly therapeutically active proteins, from an aqueous system also containing a component having the ability to create two liquid phases by use of salt partitioning technology. By the addition of water soluble inorganic salts to an aqueous system containing one or more therapeutically active proteins or nucleic acids, especially an aqueous system obtained from fractionation of a blood plasma fraction or from a tissue culture fluid resulting from a biotechnology production operation such as recombinant DNA and monoclonal antibody technologies, the aqueous system may be separated into two or more liquid phases. Such separated phases may be selectively enriched in components of the original aqueous system having differing solubility in the so-separated liquid phases.

Abstract: A blood container for storage of blood and blood components is disclosed. The invention comprises a blood container and a multiple blood bag system which includes a donor bag and one or more satellite bags connected by flexible tubing. The blood bag is made of polyvinyl chloride (PVC) plasticized with a blend of plasticizers comprising a plasticizer resistant to blood extraction such as a triester of trimellitic acid and a 7-10 carbon alcohol and a blood extractable plasticizer such as a dioctyl phthalate or dioctyl adipate and is suitable for long term storage of whole blood, red cells and platelets. The blood container is made of a thin material which contains a plasticizer composition extractable at much lower levels by blood or plasma than conventional phalate plasticized PVC. Blood and blood components processed or stored in the blood bags will exhibit relatively low levels of contamination by plasticizer.

Abstract: Normal plasma from donors who have not been vaccinated with a varicella-zoster vaccine can be screened for higher than normal titers of naturally occurring antibody to varicella-zoster virus. Those plasmas with high titers of such antibody can be pooled and fractionated to give hyperimmune globulin. The product may be treated to render it suitable for intravenous injection. Patients with varicella-zoster infection or at risk to such infection, may receive the present product to raise serum titers of varicella-zoster antibody.

Abstract: An immunizing composition is disclosed and comprises a detoxified polysaccharide from a gram-negative bacterium covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4-12 carbon moiety. To prepare the above immunizing agent, the lipid A portion of lipopolysaccharide from a gram-negative bacterium is separated to give a detoxified polysaccharide. Reactive aldehyde groups are generated on the detoxified polysaccharide by selective oxidation. The detoxified polysaccharide is then covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4-12 carbon moiety having functionalities reactive to the aldehyde groups on the detoxified polysaccharide and to the carboxylic groups on the detoxified protein.

Abstract: Normal plasma from donors who have not necessarily been vaccinated with a respiratory syncytial virus vaccine can be screened for higher than normal titers of naturally occurring antibody to respiratory syncytial virus (e.g. minimum ELISA titer of at least 1:110,000). Those plasmas with high titers of such antibody can be pooled and fractionated to give hyperimmune globulin. The product may be treated to render it suitable for intravenous injection. Patients with respiratory syncytial virus infection or at risk of such infection, may receive the present product to raise serum antibody titers to respiratory syncytial virus. Resultant product has an ELISA anti-RSV titer of at least about 1:250,000.

Abstract: There is disclosed an improved method for separating one of alpha-1-proteinase inhibitor (also known as alpha-1 antitrypsin) and antithrombin-III from an aqueous solution of plasma proteins containing the same, such as from Cohn Fraction IV-1, Cohn Fraction IV, reworks of Cohn Fraction IV and IV-1, Cohn Effluent II & III and Cohn Effluent I. The method includes the steps of first holding an aqueous solution of plasma proteins containing one of alpha-1-proteinase inhibitor and antithrombin-III in a relatively large volume of buffer solution as solvent and at a pH adjusted to be relatively basic when compared to conditions heretofore known, and at a temperature in the range of from 2.degree.-50.degree. C. for a period of about 0.2-24 hours. Following the above treatment, alpha-1-proteinase inhibitor and antithrombin-III are obtained by applying conventional techniques to the resulting solution. Accordingly, the solution is then mixed with a polyalkylene glycol, e.g.

Abstract: A shipping and storing support having recesses so constructed and arranged to ship and store selectively a plurality of articles having varying dimensions, the recesses having a plurality of internal contours for selectively receiving the articles to be retained therein by a frictional fit and wherein the plurality of internal contours of the recesses have substantially the same contour as a portion of the plurality of different sized articles adapted to be received frictionally in said recesses.

Abstract: There is disclosed an improved process for producing a concentrate containing coagulation factors VII and VIIa in relatively high purity by contacting an aqueous preparation containing factors VII and VIIa with a divalent metal salt adsorbent having selective affinity for calcium-binding coagulation factors and eluting the coagulation factors therefrom, and contacting the eluate with an anionic exchange resin and selectively eluting coagulation factors VII and VIIa therefrom by step or gradient elution techniques to obtain factors VII and VIIa in high yield, free of other coagulation factors and other proteins. In one embodiment of this invention Cohn Effluent I may be used as the source of factors VII and VIIa.

Abstract: An isotonic multipurpose blood diluent, and a method for use of this diluent with a weak lysing reagent system which is especially suitable for routine enumeration of traditional hemogram values, and also the determination of lymphoid-myeloid populations of leukocytes, particularly in automatic particle counting systems.This blood diluent is capable of affording accurate, reproducible test results. It is an osmotically balanced aqueous solution of preselected pH containing Procaine hydrochloride for maintaining erythrocyte morphology during operation, N-(2-acetamido)iminodiacetic acid (ADA) as a blood cell stabilizing agent, and bacteriostatic agents including sodium 1-hydroxypyridine-2-thione, and dimethylolurea which, together with the ADA, allow preferential determination of myeloid-lymphoid leukocytes, and other hematological values.The lysing agent is a mixture of an aqueous solution of at least one quaternary ammonium salt having surface active properties, and an alkali metal cyanide.